Jonathan Glenn

Jonathan Martin Glenn currently works at Torbay Pharmaceuticals Ltd., as Non-Executive Chairman, Aesica Pharmaceuticals GmbH, as Co-Managing Director, and The Institute of Chartered Accountants in England & Wales, as Member.
Mr. Glenn also formerly worked at Consort Medical Ltd., as Chief Executive Officer & Executive Director from 2007 to 2020, Surgical Innovations Group Plc, as Non-Executive Chairman from 2023 to 2025, Tissue Regenix Group Plc, as Non-Executive Chairman from 2020 to 2025, Pharmaron Manufacturing Services (UK) Ltd., as Director from 2014 to 2020, binx health, inc., as Director & Investor Director, Aesica Formulation Development Ltd., as Director from 2014 to 2020, Integrated Aluminium Components Ltd., as Director, Aesica Queenborough Ltd., as Director, Consort Medical Holdings Ltd., as Director, Aesica M2 Ltd., as Director, Aesica BC Ltd., as Director, Medical House Products Ltd., as Director, Consort Medical Finance 2010 Ltd., as Director, Consort Medical Finance Ltd., as Director, Aesica M1 Ltd., as Director, Celltech Group Plc, as Global Head-Finance, and Akubio Ltd., as Chief Financial Officer.